11 March 2019

GLYXAMBI® on PBS SGLT2i + DPP4i combination containing JARDIANCE® and TRAJENTA®

5 minute read

Clinicians have welcomed the Pharmaceutical Benefits Scheme (PBS) listing of the type 2 diabetes medicine that combines JARDIANCE® (empagliflozin) and TRAJENTA® (linagliptin) in a once-daily tablet

This content is for members only.
Login Join Now

End of content

No more pages to load

Register for a new account

Username

Password

Confirm Password

First Name

Last Name

Email Address

Full Name LEAVE THIS BLANK

What field do you work in?

Specialty:

Type of University work:

Industry Specialty:

Other:

Billing Address

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

Processing...

GLYXAMBI® on PBS SGLT2i + DPP4i combination containing JARDIANCE® and TRAJENTA®

Best clinical stories of 2024

PHN commissioning practices called into question

Why these junior docs donate 1% of their salary

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Log in

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover